Obesity Model and
Pharmacodynamic Service
Obesity Model and Pharmacodynamic Service
Obesity is a kind of metabolic disorder affected by many factors such as diet,environment and heredity. Besides weight gain, it may also lead to a series of complications such as diabetes, hypertension, hyperlipidemia and heart disease. In order to further study the obesity mechanism and evaluate related therapeutic drugs, Jicui Yaokang has developed a series of obesity mouse models, including diet-induced obesity model and spontaneous obesity model caused by gene mutation, and can provide drug efficacy evaluation services based on these models.
-
Obesity (DIO) model induced by 60% HFD diet: induced by 60% high-fat diet.
45% HFHSD SD diet induced obesity (DIO) model: 45% high-fat and high-sugar diet induced the model.
The mutant obese mouse model C57BL/6-ALMS1-DEL: ALMS1 gene fragment is deleted, thus forming the comprehensive phenotype of obesity, diabetes and nonalcoholic fatty liver disease.
Humanized model of obesity-related targets
Obesity-related spotted mouse (KO/CKO) model
-
Weight, food intake;
Detection of postprandial/fasting blood glucose, glycosylated hemoglobin (HbA1c), insulin and other factors (based on Elisa Kit), GTT/ITT；; Blood biochemical tests (ALT, AST, TG, Chol, HDL-C, LDL-C, etc.);
Body fat ratio test, physiological cage test (urine and feces collection), metabolic cage test (oxygen consumption, heat production, activity and other indicators); Organ collection and pathological analysis (H&E, Sirius red, Masson, Oil red, IHC, etc.);
Gene expression level analysis (q-PCR & WB), etc.